<DOC>
	<DOCNO>NCT02048111</DOCNO>
	<brief_summary>To evaluate safety ( acute adverse effect associate infusion , inhibitor development ) , pharmacokinetics ( PK ) , efficacy respect breakthrough bleed control hemorrhage prophylaxis IB1001 subject hemophilia B .</brief_summary>
	<brief_title>Study Recombinant Factor IX Product , IB1001 , Previously Treated Subjects With Hemophilia B</brief_title>
	<detailed_description>Primary Objectives : - evaluate safety IB1001 within first 50 exposure day , - determine IB1001 pharmacokinetics ( PK ) , - ass efficacy IB1001 prophylaxis respect breakthrough bleed respect control hemorrhage subject severe hemophilia B within first 50 exposure day Secondary Objectives : - evaluate long-term safety IB1001 ; - evaluate long term efficacy IB1001 . Exploratory Objectives : - evaluate marker thrombogenicity first 24 hour post-infusion [ thrombogenicity marker include minimum D-dimer test ; however clinical reason ( e.g. , three consecutive elevation D-dimer level , possible clinical thrombogenic episode ) , sufficient sample collect also evaluate level fragment 1+2 ( F1+2 ) thrombin-antithrombin III complex ( TAT ) ] - evaluate IB1001 immunogenicity response ( development inhibitory non-inhibitory factor IX binding antibody antibodies host cell protein )</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1 . Age least 12 year 2 . Body Mass Index ≤ 29 , minimum body weight 40 kg 3 . Written Institutional Review Board ( IRB ) / Ethics Committee ( EC ) approve informed consent form ( ICF ) 4 . Willingness make require study visit , follow instruction enrol study ( 12 month ) 5 . Severe ( factor IX activity ≤2 U/dL ) hemophilia B patient minimum 3 bleed episode precede 6 month 6 bleed episode precede 12 month event subject prophylaxis , minimum 3 bleed episode precede 6 month 6 bleed episode precede 12 month prior place prophylaxis 6 . Subjects must prophylaxis switch prophylaxis regimen duration PK Treatment/Continuation Phase study 7 . Previously treat patient minimum 150 exposure day factor IX preparation 8 . Willingness adhere 5day washout factor IX replacement therapy prior PK evaluation 9 . Immunocompetent ( CD4 count &gt; 400/mm3 ) receive immune modulate chemotherapeutic agent 10 . Platelet count least 150,000/mm3 11 . Liver function : alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤2 time upper limit normal range 12 . Total bilirubin ≤1.5 time upper limit normal range 13 . Renal function : serum creatinine ≤1.25 time upper limit normal range 14 . Hemoglobin ≥7 g/dL time blood draw 1 . History factor IX inhibitor ≥0.6 BU ( Bethesda unit ) 2 . Existence another coagulation disorder 3 . Evidence thrombotic disease , fibrinolysis disseminate intravascular coagulation ( DIC ) 4 . Use investigational drug within 30 day prior study entry 5 . Previous use IB1001 6 . Use medication could impact hemostasis , aspirin 7 . Hypersensitivity active substance excipients investigational product 8 . Known allergic reaction hamster proteins 9 . History poor compliance , serious medical social condition , circumstance , opinion investigator , would interfere participation compliance study protocol 10 . History adverse reaction either plasmaderived factor IX recombinant factor IX interfere subject 's ability treat bleed episode factor IX product</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>Hemophilia A</keyword>
	<keyword>Blood Coagulation Disorders , Inherited</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Coagulation Protein Disorders</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Genetic Diseases , X-Linked</keyword>
</DOC>